NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.360) was uploaded to the NHS England Website on Friday 25, April 2025.
The following changes have been introduced:
Nivolumab with ipilimumab (NIV24)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Ribociclib in combination with an aromatase inhibitor (RIB3)
Ribociclib in combination with an aromatase inhibitor as adjuvant treatment for high risk hormone receptor-positive and HER2- negative early breast cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Durvalumab in combination with chemotherapy (DUR3)
For the treatment of neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Moved into routine commissioning - section B of list
Tebentafusp (TEB1)
Tebentafusp as monotherapy for adult patients with human leukocyte antigen HLA- A*02:01 positive unresectable or metastatic uveal melanoma where the following criteria have been met
Moved into routine commissioning - section B of list
Abemaciclib in combination with endocrine therapy (ABEM3)
As adjuvant treatment for high risk hormone receptor-positive and HER2- negative early breast cancer where the following criteria have been met
Treatment criteria (#11, 12 and 15) updated
Inotuzumab ozogamicin (INO1)
The treatment of relapsed/refractory Philadelphia positive and Philadelphia negative B cell precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:
All treatment criterion updated